The End of High Cholesterol? The First Oral PCSK9 Drug Could Change Heart Medicine Forever - Dr. Norman Lepor, MD - Founder and Director, National Heart Institute

Episode notes

Send us Fan Mail Heart disease remains the leading cause of death worldwide, and one of its most important modifiable risk factors is elevated LDL cholesterol - the so-called "bad cholesterol." While statins have transformed cardiovascular care for decades, and newer therapies like injectable PCSK9 inhibitors have provided additional options, millions of patients still struggle to achieve recommended LDL cholesterol targets. In fact, despite the availability of effective therapies, roughly seventy percent of patients receiving cholesterol-lowering treatment still fail to reach guideline-recommended LDL cholesterol levels. The reasons are complex - from biology and treatment intensity to adherence and convenience - but the result is the same: preventable heart attacks, strokes, and cardiovascular deaths continue to occur. Now, a new chapter is beginning. Following years of clinical development, the FDA has approved LIPFENDRA™ (enlicitide), the first oral PCSK9 inhibitor, introducing an entirely new approach to LDL cholesterol reduction ( ). Joining us today is someone uniquely qualified to help us understand what this approval means for physicians and patients. Dr.

Related episodes across the Index

Other episodes covering the same guests and topics, from across The B2B Podcast Index.

• MDVIP's New CMO Dr. Jeffrey Lin on What Sustainable Practice Actually Looks LikeThe DocPreneur Leadership Podcast · on cardiology76 / 100
• The Evolving Landscape of Physician Practice Acquisitions with Holly Buckley of McGuireWoods LLP 6-25-26Becker Private Equity & Business Podcast · on cardiology65 / 100

• Building the Internet of Medicine: How AI Could Transform Children's Healthcare | Dr. Timothy Chou - Founder, Pediatric Moonshot92 / 100
• The Blood Test That Could Change Cancer Treatment Forever | Eric Matthews - General Manager, Biopharma, Natera65 / 100
• How Female Biology Shapes Skin Disease Across a Lifetime | Dr. Doral Fredericks, PharmD, MBA - Vice President and Head of Global Medical Affairs and Outcomes Research, Organon56 / 100
• 55 Years Without a Diagnosis | Can AI Solve The Undiagnosed Condition Blind Spot? | Haresh Patel - Founder and CEO, Sanare Health AI70 / 100
• Inside the Global Biotech Ecosystem - Where Innovation Goes Next | Sara Jane Demy - Founder and CEO, Demy-Colton